CARSO Group has acquired Bactéries et Aliments
June 2025 — CARSO Group has strengthened its leadership in the food safety sector through the acquisition of Bactéries et Aliments.
Established in 1992 and headquartered in France, CARSO is one of the leading providers of analytical services in the French market, with operations in several neighboring countries. The company offers a broad range of analyses, including water and environmental testing, occupational hygiene and building health, food safety, genetic testing and pharmaceutical analysis. In 2021, ARCHIMED became CARSO’s majority shareholder, in partnership with CAPZA, Siparex, the management team and the company’s founders. Since then, ARCHIMED has supported CARSO’s organic and external growth across Europe through targeted acquisitions and strategic partnerships in high-potential market segments. The shared objective is to further strengthen CARSO’s position as an independent, entrepreneurial and international platform in the analytical services industry.
Founded over 20 years ago, Bactéries et Aliments is a laboratory specializing in microbiological analysis. It is recognized in the field of food hygiene for its customized services, expert guidance and cutting-edge R&D activities that support development projects within the food industry.
Our role in the transaction
Oaklins’ team in France advised CARSO and its shareholders on the acquisition of Bactéries et Aliments.
Prata med transaktionsteamet
Relaterade affärer
Katalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Lär dig merLife & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Lär dig merRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Lär dig mer